It is important to note that although both D1849N and W1952* mutations identified from cancer databases help to dissect the functional significance of NF1-LRD in GBM, they are nevertheless different from mutations identified from NF1 patients who may have increased susceptibility to NF1-associated glioma. This evidence concerns the gene NF1 and glioma.